超治疗浓度锂血症持续时间延长的预测因素:一项回顾性病历回顾研究
本研究为回顾性病历回顾,纳入住院期间锂浓度>1.2 mEq/L的患者101例,排除在初始锂浓度>1.2 mEq/L后36小时内接受体外治疗者。主要分析采用Cox回归,发现年龄较大、服用噻嗪类、血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂、初始锂浓度更高及血钠浓度更高的患者达到锂浓度<1.0 mEq/L的速率更慢;达到锂浓度<1.0 mEq/L的中位时间为42.5小时(IQR 33.8–51.1)。次要分析评估Buckley等描述的列线图预测超治疗浓度锂血症持续时间延长的价值,敏感度61.5%、特异度54.5%、阳性预测值16.7%、阴性预测值90.6%。作者认为,识别血钠浓度较高及使用降低肾小球滤过率的某些降压药作为达到治疗锂浓度时间延长的预测因素,可能有助于识别符合EXTRIP血液透析标准的患者。
要点
- 达到锂浓度<1.0 mEq/L的中位时间为42.5小时(IQR 33.8–51.1),超过EXTRIP 36小时标准者常见。
- 年龄较大、服用噻嗪类/ACEI/ARB、初始锂浓度更高、血钠更高者达到锂浓度<1 mEq/L的速率更慢(Cox回归)。
- Buckley列线图预测超治疗浓度锂血症持续时间延长:敏感度61.5%、特异度54.5%、阳性预测值16.7%、阴性预测值90.6%。
- EXTRIP工作组建议:严重锂中毒符合特定标准时行血液透析,其中一项标准为优化管理下预计达到锂浓度<1.0 mEq/L的时间>36小时。
- 作者认为,识别血钠较高及使用降低肾小球滤过率降压药作为预测因素,可能有助于识别符合EXTRIP血液透析标准的患者。
适用人群与场景
- 住院期间锂浓度>1.2 mEq/L的患者。
- 排除在初始锂浓度>1.2 mEq/L后36小时内接受体外治疗的患者。
诊断标准与关键阈值
- EXTRIP工作组建议严重锂中毒符合特定标准时行血液透析,其中一项标准为优化管理下预计达到锂浓度<1.0 mEq/L的时间>36小时。
- 本研究纳入标准为住院期间锂浓度>1.2 mEq/L。
研究设计与关键结果
- 研究类型为回顾性病历回顾,纳入101例住院期间锂浓度>1.2 mEq/L的患者,排除在初始锂浓度>1.2 mEq/L后36小时内接受体外治疗者。
- 达到锂浓度<1.0 mEq/L的中位时间为42.5小时(IQR 33.8–51.1)。
- Cox回归显示,年龄较大、服用噻嗪类、血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂、初始锂浓度更高及血钠浓度更高的患者达到锂浓度<1 mEq/L的速率更慢。
- Buckley列线图预测超治疗浓度锂血症持续时间延长:敏感度61.5%、特异度54.5%、阳性预测值16.7%、阴性预测值90.6%。
- 列线图方法的表现与既往验证研究相似。
证据类型、等级与局限
- 证据类型:回顾性病历回顾。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,识别血钠浓度较高及使用降低肾小球滤过率的某些降压药(噻嗪类、ACEI、ARB)作为达到治疗锂浓度时间延长的预测因素,可能有助于识别符合EXTRIP血液透析标准的患者。
- Buckley列线图阴性预测值90.6%、阳性预测值16.7%,其表现与既往验证研究相似。
指南或共识出处
- Extracorporeal Treatments in Poisoning(EXTRIP)工作组建议:严重锂中毒符合特定标准时行血液透析,其中一项标准为优化管理下预计达到锂浓度<1.0 mEq/L的时间>36小时。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: The Extracorporeal Treatments in Poisoning (EXTRIP) workgroup suggests hemodialysis in severe lithium poisoning if specific criteria are met. One criterion is if the expected time to obtain a lithium concentration <1.0 mEq/L with optimal management is >36 h. There are a lack of data regarding which patient characteristics are associated with the rate at which patients achieve a lithium concentration <1.0 mEq/L.
METHODS: We conducted a retrospective chart review analyzing hospital electronic medical records. Inclusion criteria consisted of a lithium concentration >1.2 mEq/L during hospitalization. We excluded patients who received extracorporeal treatment before 36 h elapsed from time of initial lithium concentration >1.2 mEq/L. The primary analysis consisted of a Cox regression and a secondary analysis evaluated the nomogram method described by Buckley and colleagues for predicting prolonged supratherapeutic lithium concentration.
RESULTS: One hundred and one patients were included in the study. The median time to reach a lithium concentration <1.0 mEq/L was 42.5 h (IQR: 33.8-51.1). Older patients, patients taking a thiazide, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, patients with a higher initial lithium concentration, and patients with higher sodium concentrations achieved a lithium concentration <1 mEq/L at a slower rate. For the nomogram analysis, sensitivity (61.5%) and specificity (54.5%) were moderate, the positive predictive value (16.7%) was poor, and the negative predictive value (90.6%) was excellent.
DISCUSSION: The results from our primary analysis suggest that identifying higher serum sodium concentration and use of certain antihypertensives that decrease glomerular filtration rate as predictors of an increased time to reach a therapeutic lithium concentration may help identify patients who meet the Extracorporeal Treatments in Poisoning criteria for hemodialysis. The nomogram method performed similarly to prior validation studies.
CONCLUSIONS: In this retrospective chart review of patients with supratherapeutic lithium concentrations, we identified several risk factors for prolonged supratherapeutic lithium concentrations.
参考来源
- Ahsan S, Illg ZN, Moran TP, et al. Predictors of prolonged supratherapeutic serum lithium concentrations: a retrospective chart review. Clin Toxicol (Phila). 2024. PMID: 39105464. doi:10.1080/15563650.2024.2387654
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。